Review
Advances in clinical assessment and decision-making of intraductal papillary mucinous neoplasm in pancreas
Wang Yanwei, Cui Chenghao, Liang Yurong
Published 2023-04-28
Cite as Chin J Hepatobiliary Surg, 2023, 29(4): 316-320. DOI: 10.3760/cma.j.cn113884-20221002-00379
Abstract
Intraductal papillary mucinous neoplasm (IPMN) is one of the precancerous lesions of the pancreas. Currently there is controversial over the management and follow-up strategy of IPMN, including the timing of surgery. The core problem lies in the accurate preoperative assessment of the nature of the lesions and the risk of malignant transformation. Cumulation of high-quality evidence and development of efficient evaluation methods are vital for the establishment of standardized decision-making system and the improvement of clinical benefits to patients. This review aims to summarize the consensus and controversies on surgical evaluation standards in the latest guidelines and representative literatures, and to look forward to the development direction of IPMN diagnosis and treatment decisions in combination with the progress of related evaluation techniques.
Key words:
Pancreatic intraductal neoplasms; Clinical evaluation; Decision-making
Contributor Information
Wang Yanwei
Medical School of Chinese PLA, Beijing 100853, China
Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of Chinese PLA, Key Laboratory of Digital Hepatobiliary Surgery of PLA, Beijing 100853, China
Cui Chenghao
Medical School of Chinese PLA, Beijing 100853, China
Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of Chinese PLA, Key Laboratory of Digital Hepatobiliary Surgery of PLA, Beijing 100853, China
Liang Yurong
Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of Chinese PLA, Key Laboratory of Digital Hepatobiliary Surgery of PLA, Beijing 100853, China